Change in Statutory and Discretionary Price Concessions on Oncology Drugs. The value of gross mandatory drug manufacturer discounts has almost tripled – driven largely by the growth of 340B – putting upward pricing pressure on cancer drugs.
Change in Statutory and Discretionary Price Concessions on Oncology Drugs. The value of gross mandatory drug manufacturer discounts has almost tripled – driven largely by the growth of 340B – putting upward pricing pressure on cancer drugs.